Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04987996
Title GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients
Recruitment Suspended
Gender both
Phase Phase II
Variant Requirements No
Sponsors Providence Health & Services
Indications

head and neck squamous cell carcinoma

mucosal melanoma

uveal melanoma

melanoma

Therapies

Pembrolizumab

Belapectin + Pembrolizumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.